Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs. The company maintains its headquarters in Washington, D.C. and operates its business through research and development, clinical trial… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vanda Pharmaceuticals Inc. does
In the company’s own words
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs. The company maintains its headquarters in Washington, D.C. and operates its business through research and development, clinical trial management, and commercial operations. More information about the company can be found at www.vandapharma.com.
Vanda's commercial portfolio consists of four primary products. Fanapt® is an oral tablet approved for treating schizophrenia and acute manic or mixed episodes associated with bipolar I disorder, generating $117.3 million in net sales during 2025. HETLIOZ® is available as capsules and an oral suspension for treating Non-24-Hour Sleep-Wake Disorder in blind adults and nighttime sleep disturbances in Smith-Magenis syndrome, with 2025 net sales of $71.4 million. PONVORY® tablets treat relapsing forms of multiple sclerosis and generated $27.4 million in 2025 net sales following the company's acquisition of U.S. and Canadian marketing rights from Janssen in December 2023. NEREUSTM capsules, approved in December 2025, prevent vomiting induced by motion.
The company's development pipeline includes multiple product candidates and additional indications for existing products. Notable programs include BysantiTM, the active metabolite of Fanapt®, for bipolar I disorder, schizophrenia, and major depressive disorder; extended formulations and new indications for HETLIOZ® including jet lag disorder, insomnia, and delayed sleep phase disorder; PONVORY® for psoriasis and ulcerative colitis; NEREUSTM for GLP-1 receptor agonist-induced nausea and vomiting and gastroparesis; imsidolimab for generalized pustular psoriasis; and various early-stage programs including VTR-297 for hematologic malignancies, CFTR modulators, and antisense oligonucleotide molecules for rare neurological and hematologic conditions.
Vanda leverages expertise in pharmacogenetics and pharmacogenomics to differentiate its products and employs rigorous project management across its research and development organization. The company relies on third-party manufacturers, contract research organizations, and specialty pharmacies to support its operations and commercial distribution.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WASHINGTON, DC
- Fiscal year end
- December
- CIK
- 1347178
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vanda Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vanda Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vanda Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vanda Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vanda Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”